- Home
- IMTX vs TYRA Comparison
IMTX vs TYRA Comparison
Compare IMTX & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- TYRA
- Stock Information
- Founded
- IMTX N/A
- TYRA 2018
- Country
- IMTX Germany
- TYRA United States
- Employees
- IMTX N/A
- TYRA N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- IMTX Health Care
- TYRA Health Care
- Exchange
- IMTX Nasdaq
- TYRA Nasdaq
- Market Cap
- IMTX 579.8M
- TYRA 576.6M
- IPO Year
- IMTX N/A
- TYRA 2021
- Fundamental
- Price
- IMTX $5.61
- TYRA $9.23
- Analyst Decision
- IMTX Strong Buy
- TYRA Strong Buy
- Analyst Count
- IMTX 4
- TYRA 7
- Target Price
- IMTX $14.67
- TYRA $30.86
- AVG Volume (30 Days)
- IMTX 754.4K
- TYRA 376.4K
- Earning Date
- IMTX 08-12-2025
- TYRA 08-06-2025
- Dividend Yield
- IMTX N/A
- TYRA N/A
- EPS Growth
- IMTX N/A
- TYRA N/A
- EPS
- IMTX N/A
- TYRA N/A
- Revenue
- IMTX $155,801,989.00
- TYRA N/A
- Revenue This Year
- IMTX N/A
- TYRA N/A
- Revenue Next Year
- IMTX $1.92
- TYRA N/A
- P/E Ratio
- IMTX N/A
- TYRA N/A
- Revenue Growth
- IMTX 93.56
- TYRA N/A
- 52 Week Low
- IMTX $3.30
- TYRA $6.42
- 52 Week High
- IMTX $13.09
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- IMTX 51.00
- TYRA 41.84
- Support Level
- IMTX $5.90
- TYRA $10.11
- Resistance Level
- IMTX $6.38
- TYRA $10.68
- Average True Range (ATR)
- IMTX 0.39
- TYRA 0.79
- MACD
- IMTX -0.05
- TYRA -0.08
- Stochastic Oscillator
- IMTX 16.30
- TYRA 7.05
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.